Werewolf Therapeutics, Inc.
CAMBRIDGE, MA · Founded 2017 · CIK 0001785530 · Biotech · Public
Conditionally activated proinflammatory immune modulators for cancer treatment
werewolftx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $104M
- 2 Form D · Jan 2021
- 69 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 12 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021202220232024202520262027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $31,572,600 | |
| Private capital raised | Form D · SEC | $72,069,999 |
Form D · SECPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1441 | KJ BIOSCIENCES, LLC | — | — |
| 1442 | Centaurus Therapeutics, Inc. | — | $2.0M |
| 1443 | ACUREX THERAPEUTICS CORPORATION | — | — |
| 1444 | Werewolf Therapeutics, Inc. | — | $104M |
| 1445 | TRAILHEAD BIOSYSTEMS, INC. | — | $30M |
| 1446 | Saliogen Therapeutics, Inc. | — | $94M |
| 1447 | BRAINSTORM THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug FierceBiotech
Founders & Team
- Sakae AsanumaDirector
- Patrick BaeuerleDirector
- David CordoExecutive Officer
- Derek DiRoccoDirector
- Luke EvninDirector
- Daniel HicklinDirector · Executive Officer
- Alon LazarusDirector
- Briggs MorrisonDirector
- Elise WangDirector
- Christoph WestphalDirector
Patents
- Activatable Cytokine Polypeptides And Methods Of Use Thereofapplication
- Enhanced Adoptive Cell Therapyapplication
- Activatable INTERLEUKIN-2 Polypeptides And Methods Of Use Thereofapplication
- Activatable Cytokine Polypeptides and Methods of Use Thereofapplication
- IL-12 Prodrugs, Methods Of Use And Pharmaceutical Compositionsapplication
- Activatable Cytokine Polypeptides And Methods Of Use Thereofgranted
- Activatable INTERLEUKIN-2 Polypeptides And Methods Of Use Thereofgranted
- Activatable Interleukin 12 Polypeptides And Methods Of Use Thereofapplication
- Activatable Interleukin 12 Polypeptides And Methods Of Use Thereofgranted
- IL-2 Prodrugapplication
- Activatable Cytokine Polypeptides And Methods Of Use Thereofapplication
- Activatable Cytokine Polypeptides and Methods of Use Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.